'Will it really work?': Young sickle cell patient among the first to start new gene therapy
Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...
HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts
Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.
PharmiWeb5h
Advancing the development of CRISPR platform technologies
Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.
Yahoo News4d
'Will it really work?': Young sickle cell patient among the first to start new gene therapy
D.C., for his stem cell collection — the first major step of the revolutionary sickle cell gene therapy process. “But that also comes with the skepticism of: Will it really work?” It’s the same ...
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
STAT2h
Chinese biotech says it will start first in vivo beta-thalassemia trial
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Pharmaceutical Technology13d
Calls for increased education and support for sickle cell blood therapy in US
Sickle cell patient advocacy groups in the US are calling for greater education on the disease and increasing awareness of blood therapy.